The other study published by Michael S Hofman concluded that [177Lu]-PSMA-617 treatment has high response rates, low toxic effects, and reduces pain in patients with metastatic castration-resistant prostate cancer who have progressed after conventional treatments [40]. Here, FOLH1 is linked to prostate cancer.